Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2000 Lawrence Erlbaum Associates, Inc. Behavioral treatment of obsessive-compulsive disorder (OCD) has long been recognized as a highly effective approach to a previously intractable disorder. This type of psychological therapy has been found to be at least as effective as clomipramine, a selective serotonin reuptake inhibitor (SSRI) in the short term and is considerably better than this medication once medication is withdrawn (Kozak, Liebowitz, & Foa, chap. 25, this volume). Typically, cognitive-behavioral treatment programs report success rates of 75% or better (Abel, 1993; Abramowitz, 1996; Christensen, Hadzi-Pavlovic, Andrews, & Mattick, 1987; Stanley & Turner, 1995). Recent developments in drug treatment of OCD have resulted in newer, more selective SSRIs; however, the data may suggest that the more selective medication is to serotonin the less effective it is. Contrary to predictions from the reduced side-effect profile of the newer SSRIs, the data suggest that they do not decrease the dropout rate. Thus, even if the best interpretation is made of recent findings, development of pharmacological treatment of OCD has not resulted in an appreciable increase in treatment effectiveness. This is not to say that it is not useful to find better ways of blocking serotonin reuptake.

Original publication

DOI

10.4324/9781315561073-23

Type

Chapter

Book title

Obsessive-Compulsive Disorder: Contemporary Issues in Treatment

Publication Date

01/01/2017

Pages

201 - 221